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Abstract
Non-alcoholic fatty liver disease (NAFLD) has become over the last decade the most common form of chronic liver
disease in children and adults. Thus, establishing the diagnosis of NAFLD is of utmost importance and represents a
major challenge as the disease is generally silent and the current gold standard for diagnosis is an invasive liver
biopsy, a procedure that is not suitable for screening purposes. Many non-invasive diagnostic tools have been
evaluated so far. Recently the utility of ultrasonography for non-invasive diagnosis and estimation of hepatic
steatosis has been demonstrated in a large prospective pediatric study.
Non-alcoholic fatty liver disease (NAFLD) has become
over the last decade the most common form of chronic
liver disease in children and adults. It is tightly asso-
ciated with obesity and threatens to become a serious
public health problem in the United States and many
other countries. NAFLD is estimated to affect close to
10% of the American population aged 2 to 19 years, and
this figure increases to 30 - 40% among obese children.
In addition to being a highly common condition in
children, several lines of evidence suggest that NAFLD
is a potentially serious condition. A recent long-term
longitudinal study has demonstrated that similarly to
adults, NAFLD in children is a disease with the potential
to progress [1]. Some children in this study presented
with cirrhosis at time of diagnosis, others showed pro-
gressive liver disease resulting in significant liver-related
morbidity. Moreover, the presence of NAFLD in chil-
dren may be a key indicator of the metabolic status and
a good predictor for development of type 2 diabetes.
Thus, establishing the diagnosis of NAFLD in children
is of utmost importance and represents a major chal-
lenge as the disease is generally silent and the current
gold standard for diagnosis is an invasive liver biopsy, a
procedure that is not suitable for screening purposes.
Other screening measures have been employed,
including monitoring liver transaminases and, recently,
the American Academy of Paediatrics has recommended
that serum aminotransferases (ALT and AST) should be
performed in all overweight children starting at age 10
years if their BMI is ≥ 95th percentile or between 85-
94th percentile with risk factors. ALT and AST are to
be checked in addition to fasting glucose and lipid pro-
file. However, it has become clear that in both adults
and children liver enzymes perform poorly for NAFLD
diagnosis with two-thirds of NAFLD patients showing
normal levels of serum ALT and AST [2].
Regarding the use of imaging for screening purposes,
hepatic ultrasonography (US) is the most commonly
used modality largely because it is relatively inexpensive,
widely available and is user-friendly [3]. Several studies
in adults have demonstrated that this technique is highly
sensitive and specific for detection of NAFLD. More-
over, hepatic US can provide a good estimate of the
degree or extent of hepatic steatosis present based on a
series of US characteristics including hepatorenal echo
contrast, liver echogenicity, visualization of intrahepatic
vessels, and visualization of liver parenchyma and the
diaphragm [4-7]. In the recent years a computer-assisted
method for measuring liver echogenicity calculating the
hepatorenal index has been evaluated with good results
[8]. However, the diagnostic accuracy of hepatic US and
the utility for quantification of the degree of hepatic
steatosis in children remain unknown.
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Recently Dr Shannon A, from the Department of
Paediatric Gastroenterology, Cleveland Clinic, Cleveland,
Ohio, headed by Prof Feldstein A, conducted a study to
evaluate the utility of hepatic US for quantifying hepatic
steatosis in a large well-characterized paediatric popula-
tion with biopsy-proven NAFLD.
The manuscript entitled “Ultrasonographic Quantita-
tive Estimation of Hepatic Steatosis in Children with
Nonalcoholic Fatty Liver Disease (NAFLD)” will appear
on JPGN-NA in the August issue, and it will represent
the largest cohort of children with biopsy proven
NAFLD reported up to date [9]. In this study the
Authors demonstrate the utility of hepatic ultrasonogra-
phy for non-invasive diagnosis and estimation of hepatic
steatosis in children, showing a tight correlation
between ultrasonographic steatosis score (USS) and
severity of steatosis on liver biopsy [9]. This study con-
firms the US as now the best imaging technique for the
assessment of liver steatosis, because it is a safe, non-
invasive and non-expensive diagnostic tool. In fact, in
the recent years, magnetic resonance imaging (MRI) has
also been shown to be able to demonstrate and quantify
fat infiltration of the liver [10,11]. However, it has been
proved of limited application for the study of children
because of its lengthy scan times, its reliance on compli-
ance of the patients, with usually necessity of conscious
sedation, and its high costs. Whereas, the user-friendli-
ness of the US makes it a useful test for screening pro-
grams in paediatric patients with suspected NAFLD.
The strong correlation between US and histological
parameters of fatty liver indicates that hepatic US can
be used in the monitoring of steatosis after therapeutic
interventions in children. Therefore clinical trials having
steatosis as end-point can correctly use serial hepatic US
to estimate the response to treatment. Recently Nobili V
and co-workers demonstrated the improvement of liver
steatosis in children with NAFLD following docosahex-
aenoic acid (DHA) supplementation [12]. In this rando-
mized placebo-controlled trial liver biopsy and hepatic
US were performed at baseline. After 6 months of treat-
ment the improvement in hepatic steatosis was evalu-
ated by US examination.
In conclusion this paper disclose the way for a ratio-
nale use of US for non-invasive diagnosis of fatty liver
and for estimation of steatotis with particular regard to
monitoring therapeutic efficacy, leaving the liver biopsy
only for definition of inflammatory activity and fibrosis
stage.
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